The healthtech industry is experiencing intense competition as companies race to develop software and artificial intelligence (AI) tools for clinical decision support, medical telemetry, robotic surgery, surgical navigation, medical imaging analysis, drug discovery, clinical trial management, and countless other medical applications. This competitive landscape is driving substantial investment and rapid innovation, with established medtech providers,
With artificial intelligence tools becoming part of everyday decision-making, for some, chatbots are a first stop for help with answering questions, including questions that feel “legal” in nature. Such questions might include whether a contract clause is enforceable, how to respond to a demand letter, or what to say in an internal investigation. The AI
As innovations continue to accelerate, the technology landscape in 2026 may reach a turning point, marking a shift from research and development (R&D) to adaptation. This year’s outlook highlights a shift towards smarter, autonomous systems that operate within the physical world. Organizations that embrace this shift may thrive, while those that lag behind may risk
After years of resistance from the United States Patent and Trademark Office (USPTO) toward AI patent applications, the patent outlook for AI-related inventions in 2026 appears to be promising thanks to recent changes at the USPTO under Director John A. Squires.
On Sept. 22, 2025, the USPTO swore in Squires as its 60th director. Since
Greenberg Traurig’s Tel Aviv office collaborated with Dr. Philip Radlanski, Local Partner in the Intellectual Property & Technology Practice Group in GT Germany, on a recent interview with Calcalist, one of Israel’s leading business publications.
In the interview, Dr. Radlanski provides timely and practical guidance on how the European Union’s Artificial Intelligence
